

## IN THE CLAIMS

This claim listing replaces all the previous claim listings.

1. (Previously cancelled)
2. (Currently amended) A cyclic peptide having an amino acid sequence  
C\*C\*RGDVLDC\*, where asterisks denote to places of possible disulfide bonds,  
said sequence corresponding to apoptotically active site of human alpha-  
fetoprotein localized at amino acid residues 251-259 of said protein structure with  
a general formula of CCRGDVLD<sub>n</sub>X<sub>m</sub>Y in which formula X is any hydrophobic  
amino acid and Y is any hydrophilic amino acid, and the index n is 1, 2 or 3 and  
index m is 1, 2 or 3, said peptide having its cyclic structure through disulfide  
bonds between cystein residues corresponding to Cys251 and Cys259 of the  
protein and said peptide structure having a capability to regulate apoptotic cell  
death.
3. (Cancelled)
4. (Withdrawn) The peptide structure of Claim 3, wherein the peptide structure is  
further selected from a group consisting of linear and cyclic.
5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)


10. (Currently amended) A method for suppressing apoptotic regulatory pathways in human and animal cells by treating the cells with peptide structures according to claim 2 for an appropriate period of time.

11. (Withdrawn) A method to increase preservation of organs or cells within their transplantation by using the peptide structures of Claim 2.


12. (Withdrawn) A method to prevent autoimmune disorders and an immunodeficiency syndrome induced by a viral infection by use of the peptide structures of Claim 2.

13. (Withdrawn) A method to lower cytotoxic effects after chemo or radiotherapy by using the peptide structures of Claim 2.

14. (Currently amended) A method to inhibit cell apoptosis by using the peptide structures of Claim 2.
15. (Previously presented) The method according to claim 10, wherein the cells are cultured for scientific or technical purposes.
16. (Currently amended) The molecular peptide structure according to Claim 2, wherein the structure has an ability to bind into an antibody prepared against the molecular recognition site of a Fab-fragment or said anti-idiotypic antibody.
17. (Currently amended) The peptide structure of Claim 2, wherein the peptide is a dimer formed via disulfide bond between free cysteins of peptide monomers corresponding to Cys252 of human alpha phetoprotein polymerized.
18. (cancelled)
19. (Cancelled)
20. (Withdrawn) The peptide structure of claim 18 wherein the structure is:



21. (Withdrawn) The peptide structure of claim 18, wherein the structure is:



22. (Previously presented) The method of claim 14, wherein the apoptosis is selected from the group consisting of neuronal cell apoptosis, non-specific drug-induced apoptosis, and oxidative stress-mediated apoptosis.